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Purpose: To investigate the penetration of tacrolimus to the aqueous and serum after topical 
and oral administration.
Methods: Thirty Wistar rats were divided into three groups. In the ﬁ  rst group (n = 12), a single 
dose of 0.3 % isotonic tacrolimus solution was applied topically to the rat eyes. The second group 
(n = 12), received 0.1 mg/kg/day tacrolimus for three days. In control group (n = 6), the rats were 
administered a single drop of 0.3% salin solution topically. Following collection of samples, the 
amounts of tacrolimus in aqueous and serum samples were compared with each other. 
Results: In group I, the mean concentration of tacrolimus was 35.16 ng/ml in aqueous and 2.22 
ng/ml in serum. In group II, the mean concentration of tacrolimus was 13.08 ng/ml in aqueous 
and 13.45 ng/ml in serum. There was no signiﬁ  cant difference in the serum concentration levels 
of tacrolimus between group I and control group. However there was a signiﬁ  cant difference 
of the drug concentrations in aqueous between the groups (p < 0.001). The mean aqueous and 
serum concentrations of tacrolimus in group II, differed signiﬁ  cantly from the mean concentra-
tions in group I (p < 0.001) and the control group (p < 0.001). 
Conclusion: Tacrolimus may be a promising treatment modality in intraocular inﬂ  ammation 
by topical application besides systemic administration.
Keywords: FK506, humor aqueous, tacrolimus, penetration into the eye, systemic application, 
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Introduction
Tacrolimus (FK506) is a macrolide lactone isolated from the culture broth of Strepto-
myces tsukubaensis (Kino, Hatanaka, Hashimoto, et al 1987). It has been shown in vitro 
and in vivo to be a potent immunosuppressive agent. It is 100 times more powerful 
than cyclosporin in vitro in inhibiting T-cell proliferative responses, including mixed 
lymphocyte reactivity and cytotoxic T-cell generation (Kino, Hatanaka, Miyata, et al 
1987; Sawada et al 1987). Preclinical studies of FK506 showed prolonged corneal 
allograft survival in various animal models (Koyabashi et al 1989; Nishi et al 1993; 
Mills et al 1995; Okada et al 1996; Hikita et al 1997; Reis et al 1998). FK506 has shown 
promise in the management of corneal and limbal grafts (Dua and Azuara-Bianco 1999; 
Sloper et al 2001). It suppresses endotoxin-induced uveitis and autoimmune uveitis in 
experimental uveitis models (Hikita et al 1995; Kawashima et al 1998; Whitcup et al 
1998). FK506 was effective in the treatment of human noninfectious uveitis as well 
(Mochizuki et al 1991; Ishioka et al 1994; Kilmartin et al 1998; Sloper et al 1999). 
The efﬁ  cacy of FK506 for uveitis led us to investigate if the drug can reach thera-
peutic levels in the eye following topical and systemic application. The ﬁ  rst animal 
studies on the penetration of topical FK506 have been published by using liposomal 
and oil formulations of FK506 (Pleyer et al 1993). Clinical Ophthalmology 2007:1(1) 62
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The purpose of this experiment was to determine the 
penetration of tacrolimus into the rat aqueous humor and 
serum after topical and oral administration. For topical ad-
ministration, FK506 solution which was dissolved in castor 
oil and ethanol was used. 
Methods
Thirty adult male Wistar rats were used in this study. All 
animals were obtained from Ankara University Faculty of 
Pharmacy (Ankara, Turkey) and housed in environmentally 
controlled rooms with a 12-h light and dark cycle. All proce-
dures were performed according to the Association for Re-
search in Vision and Ophthalmology (ARVO) Statement for 
the Use of Animals in Ophthalmic and Vision Research. Food 
and water were given ad libitum. The rats were randomly 
assigned to one of 3 groups. The ﬁ  rst group (n = 12 rats), 
received only one drop of 0.3% FK506 in one eye chosen at 
random. Drops were applied using a micropipette with each 
drop containing 7 μl (Hikita et al 1997). 0.3% FK506 drops 
(Hikita et al 1997) were prepared from commercially avail-
able tacrolimus concentrate for infusion containing 5 mg ta-
crolimus, castor oil, and ethanol. The solution was preserved 
in a sterile dark colored bottle and below 25 °C. The second 
group (n = 12 rats), received 0.1 mg/kg/day tacrolimus for 
three days. The drug was given via oral gavage twice daily 
(bid). The control group (n = 6 rats), was given 7 μl drop of 
0.3% saline solution in one eye chosen randomly.
Intraperitoneal injection of ketamine was used to kill the 
animals ten minutes after topical application of the drops and 
two hours after oral administration (the mean peak concentra-
tion (tmax) time of tacrolimus is approximately 1–2 h). The 
eyes which received topical drops were carefully rinsed with 
normal saline and dried with ﬁ  lter paper to remove remaining 
drug before obtaining the samples. Aqueous humor samples 
were obtained by inserting a 27-gauge needle on a tuberculine 
syringe into the anterior chamber from the eyes. A blood 
sample was obtained by intracardiac puncture. Serum was 
collected by centrifugation of the blood sample. Tacrolimus 
concentrations in all samples were measured by microparticle 
enzyme immunoassay (MEIA).
Differences between groups were evaluated using the 
Kruskal-Wallis test for the global comparison and multiple 
comparison test for paired comparison.
Results
Tacrolimus concentrations were determined in aqueous hu-
mor and serum at 10 min after topical and 2 h after systemic 
administrations. In all experiments no ocular side effects were 
observed in animals receiving topical drops. In group I, (topical 
tacrolimus applied eyes), the mean concentration of tacrolimus 
was 35.16 ± 4.26 ng/ml (31–42 ng/ml) in aqueous humor. The 
serum levels ranged between 1.3 to 7.6 ng/ml with the mean 
being 2.22 ± 3.14 ng/ml in this group. In the second group, (oral 
tacrolimus-given rats), the mean concentration of tacrolimus 
was 13.08 ± 1.08 ng/ml (10–17 ng/ml) in aqueous humor and 
13.45 ± 5.5 ng/ml (9.3–20.8 ng/ml) in serum. 
Negative controls were performed on serum and aque-
ous humor from animals receiving topical saline solution. 
No measurable FK506 drug concentrations were detected 
in aqueous humor and serum in this group. 
The mean drug concentrations in aqueous humor differed 
signiﬁ  cantly between all groups (p < 0.001). However, there 
was no signiﬁ  cant difference in the serum concentrations 
between group I and the control group. The mean aqueous 
humor and serum concentrations of tacrolimus in group II 
differed signiﬁ  cantly from the mean concentrations in group 
I (p < 0.001) and the control group (p < 0.001). 
Discussion
The results of this study indicate that topically applied 
tacrolimus resulted in high concentrations of the drug in 
aqueous humor, but low levels of tacrolimus in serum in 
rats. An additional ﬁ  nding is that signiﬁ  cantly higher drug 
concentrations were obtained in aqueous humor and serum 
after oral administration. 
Animal studies indicate tacrolimus is widely distributed 
into most tissues including the lungs, spleen, heart, kidney, 
pancreas, brain, muscle, and liver. It is present in breast milk 
at similar levels to those reported in the plasma (Scott et al 
2003). Since the greater the lipid solubility coefﬁ  cient of a 
substance, the greater its ability to penetrate the blood-aque-
ous barrier, tacrolimus is expected to pass the blood-aqueous 
barrier easily. In our study, the aqueous humor concentrations 
of tacrolimus were high and close to serum concentrations 
in the oral tacrolimus group.
FK506 has been shown to be a potent immunosuppres-
sive agent in several models of organ transplantation and 
in clinical practice. The concentrations required to control 
immune-mediated diseases of the eye have not been estab-
lished. However, organ transplantation studies show serum 
concentrations of tacrolimus for immunosuppressive effect 
should be in the range of 5–15 ng/ml (Pirsch et al 1997) which 
can be considered the effective target organ concentration to 
control immune  response. In our study, the serum concen-
tration was 2.22 ± 3.14 ng/ml after topical and 13.45 ± 5.5 
ng/ml after oral administration. Clinical Ophthalmology 2007:1(1) 63
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Tacrolimus is poorly absorbed from the gastrointestinal 
tract (Honbo et al 1987). However, a solid dispersible for-
mulation of tacrolimus in hydroxypropyl methylcellulose 
was developed for clinical use which has rapid oral absorp-
tion and good stability (Honbo et al 1987). We used 0.1 
mg/kg/day tacrolimus which has this formulation by oral 
route and obtained therapeutic concentrations in aqueous 
humor and serum. 
FK 506 is a 23-membered macrolide lactone with a mo-
lecular weight of 822 g/mol. This hydrophobic compound 
has low solubility in aqueous solutions but it dissolves read-
ily in alcohols and some oils (Kino, Hatanaka, Hashimoto, 
et al 1987). In our experiment, tacrolimus solution which 
was dissolved in castor oil and ethanol was used for topical 
application.  
Pleyer and colleagues (1993) investigated the systemic 
and ocular absorption of topically applied FK506 in rabbits. 
They used liposomal and oil formulations of FK506. They 
detected low intraocular drug concentrations after the topi-
cal application of FK506 dissolved in olive oil but obtained 
higher drug concentrations with liposome-bound FK506 in 
aqueous humor and vitreus. Liposomes increase corneal drug 
absorption and have tendency to accumulate in the conjunc-
tival folds (Fitzgerald et al 1987). Conjunctival and scleral 
penetration is important in delivering poorly absorbed drugs 
to intraocular tissues. 
The penetration of topical and systemic tacrolimus into 
aqueos humor reached a high concentration in our study. 
This result is different from the ﬁ  ndings with the topical ap-
plication of FK506 dissolved in olive oil (Pleyer et al 1993). 
This difference may be due to combination of castor oil and 
ethanol in formulation we used in our study. This particular 
drug formulation penetrated well into the eye compared with 
only oil-based formulations. Since tacrolimus is very soluble 
in alcohols (Kino, Hatanaka, Hashimoto, et al 1987; Tanaka 
et al 1987), the addition of ethanol to castor oil increased 
its solubility.  
Side effects of the drug include kidney damage, trem-
ors, high serum pressure, diabetes, high serum potassium, 
headache, insomnia, confusion, and seizures. Cosmetic 
complications such as gum hyperplasia and hirsutism are 
less commonly associated with tacrolimus than cyclosporin 
(Reyes et al 2000). Local ocular immunosuppression provides 
adequate therapeutic level of local immunosuppressive activ-
ity while avoiding the risk of generalized immunosuppression 
and systemic adverse reactions. In addition, serum levels of 
tacrolimus have to be measured regularly in systemic use 
because of variable absorption after oral administration. 
From the data observed in the present study, we conclude 
that high aqueous humor and serum levels of tacrolimus were 
obtained after systemic, and high aqueous levels were also 
obtained after topical administration. The drug concentrations 
are between the minimal effective concentration levels (5–15 
ng/ml) to control the immune response in immune-mediated 
eye diseases. 
This experiment was designed as an absorption study not 
a pharmacokinetic study. Drug levels at different time courses 
were not studied. Further studies to obtain a time course of 
the drug levels following administration would be useful 
how long were these drug levels maintained.
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